Anthem Biosciences Ltd. Q1 FY27 Earnings Call Summary

Revenue

Margin

Demand

Guidance

Tone

Event Participants

Executives

2 Ajay Bhardwaj, Gawir Baig

Analysts

10 Bansi Desai, Bino Pathiparampil, Dhaval Khut, Mehul Sheth, Parth Sodha, Saion Mukherjee, Sajal Kapoor, Tushar Manudhane, Udit Bokaria, Vivek Agarwal

Financials & KPIs

Metric	Reported	Commentary
Revenue from operations	₹418 crores	Q1 FY27 consolidated; soft quarter driven by customer delivery timing shifts, with higher scheduled deliveries in H2; no YoY figure disclosed by management
CRDMO revenue	₹341 crores	81.5% of total revenue; quarter impacted by deferrals; management expects recovery in Q2-Q4
Specialty Ingredients revenue	₹78 crores	18.5% of total revenue; domestic B2B business; raw material supply chain turmoil weighed on the quarter
EBITDA (incl. other income)	₹176 crores	EBITDA margin ~39.6%; management cited YoY margin improvement
Other income	₹25 crores	Included in EBIT/EBITDA as per management commentary
PBT	₹145 crores	After other income; Q1 tax rate low (normalization expected at ~25-25.5%)
PAT	₹120 crores	PAT margin 27.1%; YoY improvement per management
Net cash	₹1,720 crores	As of June 30, 2026
Order book visibility	~60% of FY27 requirement	For whole business; order book replenished in Q1 despite soft deliveries
Capacity utilization	Unit 1: ~78%; Unit 2: ~50% (custom synthesis) & ~50% (fermentation); Unit 3: 30–35%	Unit 1 custom synthesis vs ~74% FY26 exit; Unit 3 up from ~15% in FY26; ramp-up continuing
FY27 capex	~₹700 crores	Largely Unit 4 Phase 1; total Unit 4 outlay ₹1,200 crores, commissioning by end FY28
ESOP cost FY27	~₹9 crores	Down from ₹16 crores in FY26; further decline to ~₹5 crores in FY28
Effective tax rate FY27E	~25–25.5%	Normalizing from low Q1 rate; Neo Anthem expected to turn profitable this year

Geographic & Segment Commentary

CRDMO: Contributed 81.5% of consolidated revenue (₹341 crores) in Q1 FY27. Quarter was impacted by customer delivery deferrals, but order book visibility stands at ~60% of full-year needs. Pipeline: 100+ early-stage programs, 10 late-phase molecules, with 4 molecules commercialized by customers last year; one new Big Pharma customer onboarded and one biotech client (late Phase 3) acquired by Big Pharma.
Specialty Ingredients: Contributed 18.5% of revenue (₹78 crores); largely an India-focused, month-on-month B2B business. Q1 was impacted by raw material supply chain disruptions (geopolitical); management expects "very decent growth" by FY27-end with improved visibility.
Manufacturing network: Unit 1 ~78% utilization (custom synthesis); Unit 2 ~50% across expanded custom synthesis capacity and ~50% fermentation (140 KL); Unit 3 (Neo Anthem) at 30–35% vs ~15% FY26. Unit 4 is under construction—365 KL custom synthesis, 100 KL fermentation, plus a food & nutra plant—targeted for commissioning by end FY28.

Company-Specific & Strategic Commentary

Revenue lumpiness & order book: Management explicitly flagged CRDMO delivery lumpiness and advised investors to evaluate performance on a YoY basis rather than QoQ. ~60% of the full-year order book for the entire business is already secured and was replenished even after Q1.
Customer additions & M&A: One new Big Pharma customer was added in Q1; the agreement is not yet signed but contribution is expected from later quarters of FY27. One large biotech customer (late Phase 3 development contract) was acquired by Big Pharma ~a month ago; no material FY27 impact expected, but it provides a "foot in" for long-term relationship.
GLP-1 / Semaglutide API: Scale-up and trials are complete; commercial supply awaits CDSCO approval, expected within a quarter or two. Most major domestic players have been sampled; overseas customers have also been sampled, but exports are not yet targeted. No GLP-1 revenue booked yet; management calls it a "long-term very robust opportunity."
Technology & margin defense: Management cites flow chemistry, bio-catalysis, backward integration, and yield optimization as structural margin drivers; material margin improved even in a weak revenue quarter. AI is being evaluated for QA document review and manufacturing optimization; management sees AI-accelerated drug discovery as incremental CRDMO demand.
Unit 4 capacity expansion: ₹1,200 crores Phase 1 capex on a ~30-acre site; FY27 capex ~₹700 crores; adds 365 KL custom synthesis, 100 KL fermentation, and food/nutra manufacturing. Civil work is nearly complete and equipment orders are being placed; commissioning targeted for end FY28.

Guidance & Outlook

Metric	Guidance / Outlook	Commentary
FY27 revenue growth	Long-term double-digit historical growth; no specific percentage guidance	Q1 deferrals to be recovered in Q2-Q4; ~60% order book coverage; management "very confident" of full-year growth
FY27 EBITDA & PAT margins	Sustain near Q1 levels (~39.6% EBITDA, ~27.1% PAT); YoY improvement	Order book locked in; cost efficiencies and yield optimization; new unit ramp-ups can temporarily pressure PAT in coming years
Effective tax rate FY27	~25–25.5%	Normalizes from low Q1 rate as Neo Anthem moves toward break-even/profitability
Cost ratios FY27	Employee cost ~13% of sales; other expenses ~9–10%	Q1 employee cost at 18.8% due to muted revenue; no one-off expenses
Capex	~₹700 crores FY27; Unit 4 total ~₹1,200 crores (roughly 50:50 split FY27/FY28)	Civil works near completion; equipment orders being placed; commissioning end FY28
Capacity utilization	Ramp to near-optimum across Units 1-3 over next 2 years	Unit 4 (+365 KL custom synthesis, +100 KL fermentation) needed as existing units fill
Neo Anthem profitability	Expected break-even/profitable in FY27	Supports normalized tax rate and consolidated margin profile

Risks & Constraints

Risk	Context
Quarterly revenue lumpiness	Q1 FY27 was a soft quarter (an analyst cited ~25% YoY decline; management did not dispute). Customer delivery deferrals are inherent to the CRDMO model; management expects Q2-Q4 recovery but warns that QoQ swings, including "bumper" quarters, should not be read as trends.
Big Pharma M&A uncertainty	One biotech client was acquired by Big Pharma; the contract is a late Phase 3 development program, so pipeline re-evaluation and commercial award are key milestones. No meaningful discussions with the acquirer have occurred yet; outcome could be positive (sticky relationship) or negative (program deprioritization).
Regulatory approval timing	Semaglutide API awaits CDSCO approval—all scale-up work is done but no revenue booked. Management expects approval within a quarter or two, but timelines are outside company control; no US FDA/EU inspection timeline for Unit 3 was provided.
Margin sustainability	EBITDA margin ~39.6% is industry-leading; management defends it via order book visibility and technology moats, but specialty molecules commoditize over time, and Unit 4 ramp-up/depreciation could pressure margins over the next 3-5 years.
Capex execution	Unit 4 Phase 1 outlay of ₹1,200 crores, with ₹700 crores in FY27; construction, equipment installation, and customer qualification of new capacity carry execution risk. Net cash of ₹1,720 crores is available, but no financing details were discussed.
Specialty Ingredients supply chain	Domestic B2B business was hit by raw material turmoil (geopolitical); management sees recovery and "decent growth" in FY27, but input cost and availability remain watch items.

Q&A Highlights

Capacity utilization and Unit 4 ramp-up

Question: Update on capacity utilization at Units 1, 2 and Neo Anthem, expected trajectory over next 3 years, and any US FDA/EU inspection timeline for Unit 3? (Saion Mukherjee, Nomura)
Answer: (Gawir Baig) Unit 1 is ~78% utilized on custom synthesis (vs ~74% FY26 exit); Unit 2 is ~50% across expanded custom synthesis capacity and ~50% on 140 KL fermentation; Unit 3 is 30–35% vs ~15% FY26. Expect near-optimum utilization across all units within 2 years, which is why Unit 4 is being built; regulatory inspection timeline was not addressed.
Question: Status of Unit 4, capex incurred, outlay for next 2 years, commissioning timeline? (Mehul Sheth, HDFC Securities)
Answer: (Gawir Baig) Unit 4 Phase 1 outlay ~₹1,200 crores on ~30 acres; adds 365 KL custom synthesis, 100 KL fermentation, plus food & nutra plant. Ground broken last year; commissioning by end FY28; capex roughly 50:50 split across FY27 and FY28. FY27 total capex ~₹700 crores (follow-up from Bino Pathiparampil, Elara Capital).

Order book and FY27 growth

Question: How should we interpret the 60% visibility; what is the remaining 40%, and is this whole-business or CRDMO-only? (Udit Bokaria, Catamaran)
Answer: (Ajay Bhardwaj) Specialty Ingredients is a month-on-month, largely India-focused business with rolling forecasts; CRDMO R&D contracts give 1–2 quarter predictability. (Gawir Baig) The 60% order book coverage is for the whole business and remains at ~60% even after Q1; remaining portion comes from new clients, existing customer volume increases, and clinical-stage pull-through.
Question: Q1 is down ~25% YoY; does the full-year CRDMO growth target hold? (Mehul Sheth, HDFC Securities)
Answer: (Gawir Baig) Long-term double-digit growth is intact; Q1 shortfall will be recovered in Q2–Q4. (Ajay Bhardwaj) Investors should look at YoY, not QoQ—there will be both soft and "bumper" quarters. On a follow-up, management declined to commit to a specific 20% figure but affirmed historical growth trajectory (Bino Pathiparampil, Elara Capital).

Customer traction, M&A, and pipeline

Question: Any update on new contracts, Big Pharma traction, peptide initiatives, and when new client revenue kicks in? (Saion Mukherjee, Nomura)
Answer: (Ajay Bhardwaj) One new Big Pharma customer onboarded; agreement not yet signed but engagement is multi-dimensional (R&D, new projects, supply chain diversification), with revenue expected in later quarters of FY27. One large biotech customer was acquired by Big Pharma ~a month ago; 100+ early-stage and 10 late-phase programs, with a couple of ADCs in late phase and peptides mostly early-stage (Gawir Baig).
Question: Are lateral projects and commercialized molecules progressing with existing Big Pharma clients? (Udit Bokaria, Catamaran)
Answer: (Ajay Bhardwaj) New customers typically leave existing teams/assets untouched for 1–2 years post-acquisition; a customer onboarded last quarter is already sending advanced starting material and intermediate inquiries. Relationships mature over 3–4 years, so early traction will scale gradually.

Biotech acquisition implications

Question: How does the acquisition of a biotech customer by Big Pharma change demand for that project? (Vivek Agarwal, Citi)
Answer: (Ajay Bhardwaj) No material impact for FY27; acquirers usually leave teams alone for 1–2 years. No meaningful discussions with the acquirer yet, but it provides a "foot in" with Big Pharma. (Gawir Baig / Ajay Bhardwaj) The contract is a late Phase 3 development contract, not a commercial supply agreement; commercial conversion depends on further clinical/regulatory progress (follow-up from Tushar Manudhane, Motilal Oswal).

GLP-1 / Semaglutide API

Question: Have we started commercial supply to domestic players; are we seeing inbound queries due to peer scale-up issues? (Bansi Desai, JP Morgan)
Answer: (Ajay Bhardwaj) Commercial supply has not started; CDSCO approval is pending. Trials and scale-up are complete and most major domestic players have been sampled. Approval is expected this year, likely within a quarter or two; no other market is targeted yet, though overseas customers have been sampled (follow-up from Dhaval Khut, Jefferies).

Margins and cost structure

Question: What gives confidence that industry-leading margins sustain over the next 3–5 years? (Bansi Desai, JP Morgan)
Answer: (Ajay Bhardwaj) FY27 margins are protected by the ~60% order book; technology (flow chemistry, bio-catalysis), backward integration, and yield optimization drive cost leadership. Material margin improved even in a soft revenue quarter; new unit ramp-ups can temporarily depress PAT, but margins should be defended.
Question: Any one-off in other expenses; how should FY27 cost ratios be modeled? (Vivek Agarwal, Citi)
Answer: (Gawir Baig) No significant one-offs; raw material margin is consistently improving. Q1 employee cost at 18.8% of sales reflects muted revenue; full-year should be ~13%. Other expenses should be ~9–10% of sales. ESOP cost is ~₹9 crores for FY27 vs ₹16 crores in FY26, declining to ~₹5 crores in FY28 (follow-up from Bansi Desai, JP Morgan).

Tax rate

Question: Will the low Q1 tax rate normalize to ~25%? (Bino Pathiparampil, Elara Capital)
Answer: (Gawir Baig) Yes, FY27 effective tax rate should be ~25–25.5%. FY26 was elevated due to losses at Neo Anthem; Neo Anthem is expected to break even or turn profitable this year.

Specialty Ingredients and Q1 as trough

Question: Is Q1 the lowest quarter of FY27, and when does Specialty Ingredients return to growth? (Dhaval Khut, Jefferies)
Answer: (Ajay Bhardwaj) Q1 is clearly the softest quarter; growth resumes from Q2 onward. Specialty Ingredients was hit by raw material supply chain turmoil (geopolitical), but visibility has improved and "very decent growth" is expected by FY27-end.

Deferral mechanics

Question: Why would customers defer deliveries on products that are still growing YoY? (Udit Bokaria, Catamaran)
Answer: (Ajay Bhardwaj) Customers rebalance inventory across geographies when regional demand and approval timelines slip (e.g., stocking in China/Germany/France, rerouting material to other markets). Confirmed orders remain intact—only timing shifts; this affects quarterly distribution, not the overall business.

AI and competitive moat

Question: How will AI structurally impact Anthem's business over the next 5 years? (Saion Mukherjee, Nomura)
Answer: (Ajay Bhardwaj) AI is still early-stage with "a lot of hype"; Anthem is evaluating document review/QA automation and manufacturing resource optimization. If AI accelerates drug target discovery, Anthem expects incremental discovery and manufacturing work—a net positive over 3–4 years.
Question: What do customers value most when choosing Anthem over other CRDMOs? (Sajal Kapoor, Antifragile Thinking)
Answer: (Ajay Bhardwaj) Customers value keeping promises and contributing innovation/IP beyond being "a pair of hands", plus a strong regulatory compliance track record and quality of people; 360-degree employee training is a key differentiator.

Key Takeaway

Anthem Biosciences' Q1 FY27 was a deliberately soft quarter, with consolidated revenue of ₹418 crores (CRDMO ₹341 crores, Specialty Ingredients ₹78 crores) as customers shifted deliveries to H2; EBITDA of ₹176 crores and PAT of ₹120 crores still delivered ~39.6% EBITDA and 27.1% PAT margins with YoY improvement. Management kept guidance qualitative—double-digit FY27 growth consistent with history—backed by ~60% full-year order book visibility, replenished even after Q1, and capacity utilization poised to recover from Q1 levels (Unit 1 ~78%, Unit 2 ~50%, Unit 3 ~35%). Strategic catalysts include a new Big Pharma onboarding, a late-Phase 3 biotech client acquired by Big Pharma, Semaglutide API awaiting CDSCO approval, and ₹1,200 crores Unit 4 capex (₹700 crores in FY27) commissioning by end FY28. Watch items: quarterly lumpiness, regulatory timelines, and margin defense as the company scales.